



Medlab UNSW Sydney Laboratory Media Release

SYDNEY, August 01, 2022 - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), an Australian biotech using delivery technology to enhance medicines effectiveness, is pleased to update a new initiative with UNSW Sydney.

- Medlab is entering into a laboratory collaboration-space lease agreement with the UNSW, Sydney in early August. This will build on current collaborations Medlab, and UNSW are working on – namely the NanoCelle® RNA nasal delivery research program.
- Medlab Clinical is delighted to announce that we now have a laboratory located in the UNSW School of Biotechnology and Biomolecular Sciences (BABS), which is one of Australia's most prestigious schools of scientific research and teaching.
- Medlab is impressed by the progress of the current collaboration with UNSW's RNA Institute and the Woolcock Institute to develop nasal spray delivered RNA vaccines and antiviral treatments; and also advance nasal spray delivered insulin. These collaborations are leveraging Medlab Clinicals NanoCelle® delivery technology.
- Closure of the Alexandria facility, the opening of pharmaceutical facilities in Botany [inclusive of warehousing, secure drug vaults, stability chambers, and retention sampling areas] and the laboratory lease with UNSW, will provide Medlab significant operational expenditure savings and new research development capabilities and opportunities.

- ENDS -

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical LTD (ASX:MDC) is pioneering the development and Commercialisation of a delivery technology, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain.

NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory.

NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit www.medlab.co

Medlab – *better medicines, better patient care*

For further information contact:

Dr. Sean Hall, CEO

Medlab Clinical Ltd

T: +61 411 603 378 E: sean_hall@medlab.co